National Bank of Canada
VRDN icon

National Bank of Canada’s Viridian Therapeutics VRDN Stock Holding History

National Bank of Canada’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-100
Closed -$2.27K – 3231
2024
Q3 		$2.27K Buy
+100
New +$1.64K ﹤0.01% 2342

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

National Bank of Canada's VRDN Position: Q4 2024 in Review

National Bank of Canada sold out of Viridian Therapeutics (VRDN) in Q4 2024, closing a stake of 100 shares — an estimated $2.27K sold.

National Bank of Canada first reported a position in VRDN in Q3 2024 and held it in 1 quarter. The position peaked at $2.27K in Q3 2024. 178 funds tracked by Wall St. Rank hold VRDN as of Q4 2024.

  • National Bank of Canada reported no remaining Viridian Therapeutics position as of Q4 2024 after selling out during the quarter.
  • National Bank of Canada sold 100 Viridian Therapeutics shares in Q4 2024, an estimated $2.27K.
  • National Bank of Canada first reported a position in Viridian Therapeutics in Q3 2024 and held it in 1 quarter.
  • National Bank of Canada's Viridian Therapeutics position peaked at $2.27K in Q3 2024.
  • 178 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2024.

Based on National Bank of Canada's 13F filing for Q4 2024, filed 12 Feb 2025.